Biotechnology

Mabwell

Mabwell Biologics Receives FDA Approval for 9MW5211 Clinical Trials

Mabwell Biologics' 9MW5211 Clinical Trial Application Approved by FDA

MaiWei Biopharma Discloses Latest Clinical Trial Results for Novel ADC for Cervical Cancer Treatment

Mabwell released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 127.6 M, actual EPS CNY -0.61

Mabwell FY2026 Q1 Earnings Release on April 29 After-Market (BJT)

Mabwell to Release FY2025 Earnings on March 25 Pre-Market (BJT), Forecast Revenue CNY 709.5 M, EPS CNY -1.795

Mabwell released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 96.68 M, actual EPS CNY -0.9274

Mabwell released FY2025 earnings on February 27 Pre-Market (BJT), actual revenue CNY 662.52 M (forecast CNY 709.5 M), actual EPS CNY -2.43 (forecast CNY -1.795)

Mabwell FY2025 Q3 Earnings Release on October 31 After-Market (BJT)

Mabwell released FY2025 Q3 earnings on October 21 After-Market (BJT), actual revenue CNY 464.67 M, actual EPS CNY -0.1169

Mabwell released FY2025 9 Months Earnings on October 21 After-Market (BJT), Actual Revenue CNY 565.84 M, Actual EPS CNY -1.4969

Mabwell released FY2025 Q2 earnings on August 29 During-Market (BJT), actual revenue CNY 56.38 M, actual EPS CNY -0.6499

Mabwell released FY2025 Semi-Annual earnings on August 29 During-Market (BJT), actual revenue CNY 101.17 M, actual EPS CNY -1.38

Mabwell to Release FY2025 Semi-Annual Earnings Report on August 30, 2025, BJT

Mabwell's Bulumtatug Fuvedotin Clinical Trial Treats First Patient

Maiwei Biologics CEO Liu Datao Penalized by CSRC for Short-term Trading

Maiwei Biologics Increases Stock Repurchase Price Cap

MabWELL Bio's 7MW4911 Clinical Trial Application Accepted by NMPA and FDA

Mabwell Biologics Achieves Revenue Growth, License Deals Optimize Cash Flow

Mabwell Biologics Publishes International Patent for Anti-FAP Antibody

02493

688062

Mabwell has received FDA clearance for its IND application for 9MW5211, a novel antibody aimed at treating inflammatory bowel disease (IBD). This marks the world's first clinical-stage drug candidate targeting this condition. The antibody selectively depletes pathogenic immune cells, potentially improving patient outcomes. Clinical trial applications for multiple indications, including IBD and multiple sclerosis, are under review in China. Preclinical studies indicate significant therapeutic potential, and safety evaluations show a favorable profile. Mabwell aims to enhance treatment accessibility and effectiveness in autoimmune diseases.

prnewswire

MABWELL-B

20:00 ETWorld's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Application

Mabwell (Shanghai) Bioscience Co., Ltd. has received FDA clearance for a first-in-human trial of its antibody candidate 9MW5211, aimed at treating inflammatory bowel disease. The trial will assess safety and tolerability in healthy subjects. The drug targets pathogenic immune cells and has shown promising preclinical results. Mabwell is expanding its global presence in autoimmune therapies, despite the uncertainties of drug development. The success of 9MW5211 could lead to significant market opportunities and improved patient outcomes, although future approvals depend on trial results and regulatory decisions.

Tip Ranks

Mabwell Wins FDA Green Light for First-in-Human Trial of Novel Autoimmune Antibody 9MW5211

Mabwell (Shanghai) Bioscience Co., Ltd. plans to issue targeted debt financing instruments of up to RMB 1 billion to optimize its capital structure. The bonds, with terms of up to three years, will be issued in the interbank bond market to institutional investors. Proceeds will be used for repaying liabilities, funding project construction, and replenishing working capital. The board has approved the proposal, pending shareholder approval and regulatory clearance. Mabwell focuses on developing innovative biologic therapies and is listed in Hong Kong.

Mabwell Plans Up to RMB 1 Billion Targeted Debt Issue to Reshape Capital Structure

Mabwell (Shanghai) Bioscience Co., Ltd. has announced a shift to electronic corporate communications for non-registered shareholders, complying with Hong Kong Listing Rules. Future reports and documents will be available in English and Chinese on the company's website and the Hong Kong Stock Exchange platform, eliminating individual notifications. Shareholders preferring hard copies can request them, but requests will only be valid until the end of the next financial year. This move emphasizes a transition towards digital communications in the biopharmaceutical sector.

Mabwell Moves Non-Registered Shareholders to Digital Corporate Communications

Mabwell (Shanghai) Bioscience Co., Ltd. has officially listed on the Main Board of the Hong Kong Stock Exchange (HKEX) as of April 28, 2026. The company, founded in 2017, specializes in innovative pharmaceuticals with a focus on oncology, immunology, and other therapeutic areas. Mabwell boasts a diverse product pipeline, including 4 commercialized products and 10 drug candidates, with significant advancements in antibody-drug conjugates (ADCs). The company has also expanded its global market presence through strategic partnerships and commercialization efforts in various countries.

Asian Corporate Newswire

Empowered by Pipeline and Forged by Technology: Mabwell Successfully Lists on the Main Board of HKEX

Mabwellhas initiated a Phase III clinical study for its Nectin-4-targeting ADC, 9MW2821, aimed at treating triple-negative breast cancer (TNBC). This ADC is the first of its kind to enter Phase III trials for TNBC and has received Fast Track Designation from the FDA. The study will compare 9MW2821's efficacy against standard chemotherapy in patients with advanced TNBC who have previously undergone taxane-based treatments. TNBC is known for its aggressive nature and lack of clear therapeutic targets, representing a significant unmet medical need.

04:14 ETMabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer